TOI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. TOI is in a clear short-term downtrend (regular session -5.24%) with bearish momentum still accelerating (negative, expanding MACD). Despite being deeply oversold (RSI_6 ~17), there is no Intellectia buy signal and the pattern-based outlook remains negative over the next week/month. I would avoid new entries here; if already holding, this setup leans toward reducing/exiting rather than adding.
Price/Trend: Sharp downside move in the regular session (-5.24%) with only a modest post-market bounce (+2.58%), suggesting sellers remain in control. Momentum: MACD histogram -0.0973 and negatively expanding = bearish momentum strengthening, not stabilizing yet. RSI: RSI_6 at 16.981 is deeply oversold, which can produce a short bounce, but oversold alone is not a buy trigger when MACD is still worsening. Moving Averages: Converging MAs implies compression/transition, but the momentum profile points to a bearish resolution in the near term. Levels: Pivot 3.188 is well above current (~2.71–2.78), so the stock is trading below key reference resistance. Nearby support: S1 2.815 (already trading around/under it), then S2 2.585 as the next downside level. Resistance: R1 3.56 then R2 3.79, meaning any bounce faces heavy overhead supply.
Intellectia Proprietary Trading Signals Intellectia Proprietary Trading Signals
with a Buy and $5 PT, citing durable 20%+ growth potential and margin expansion as value-based care mix increases; expects positive EBITDA in Q4 and FY
Financial growth: 2025/Q3 revenue +36.70% YoY to $136.6M shows strong top-line momentum. No insider selling trend: insiders are neutral over the last month.
and flirting with/under S1 (2.815), with S2 at 2.585 as the next risk area. Smart-money signal: Hedge funds are selling aggressively (selling amount up 47,487.34% over the last quarter). Profitability/margins: Gross margin fell to 12.59% (down 1.72% YoY); EPS declined to -0.14 (down 22.22% YoY), indicating operating leverage is not yet translating into per-share improvement. Forward near-term pattern risk: Similar-pattern forecast implies a negative bias (-2.22% next week, -2.03% next month). News/catalyst vacuum: No notable news in the last week to force a reversal or re-rate the stock immediately. Influential buying/selling: No recent congress trading data available in the last 90 days; no politician/influential-figure activity provided to support a near-term sentiment shift.
Latest reported quarter: 2025/Q3. Revenue grew strongly to $136.564M (+36.70% YoY), indicating demand/expansion momentum. Losses narrowed slightly in net income terms (Net Income -$13.77M, +4.14% YoY improvement), but per-share results worsened (EPS -0.14, -22.22% YoY) and gross margin slipped to 12.59% (-1.72% YoY). Overall: strong growth, but profitability and margin trajectory still not clean—important given the stock’s high volatility and the market’s current risk appetite.
Recent trend: Coverage was initiated (2025-11-25) by Needham with a Buy rating and a $5 price target; no downgrades/target cuts are shown in the provided data. Wall Street pros view (bull case): value-based care adoption could expand margins to mid-single digits and sustain 20%+ growth; shares viewed as undervalued ahead of expected positive EBITDA (Q4/FY26). Cons view (pushback from the tape/data): hedge funds are selling, technicals are decisively bearish near-term, and margins/EPS are not yet improving enough to support impatient, momentum-style buying today.
